# US 2008/0287384 A1 · Methods of Identifying Agents Having Antiangiogenic Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287384 A1
- Document ID: US20080287384A1
- Status: Published application
- Kind: A1
- Application number: 12/067,356
- Filed: 2006-09-19
- Published: 2008-11-20
- Earliest claimed: 2005-09-19
- Inventors: Marsha Rosner; Wei-Jen Tang; Jia Hong
- Web page: https://patentgrep.com/patent/US20080287384A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/164: {from bacteria}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are assays and methods of identifying antiangiogenic agents including contacting an endothelial cell with a putative antiangiogenic agent and assaying for activation of Rap-1 in the endothelial cell. Also provided are methods of inhibiting angiogenesis and treating conditions associated with improper angiogenesis. Compositions comprising activators of Rap-1 and methods of activating the Rap-1 signaling pathway are also provided. Methods of inhibiting chemotaxis and angiogenesis by contacting cells with Rho inhibitors are provided.

## Claims

### Claim 1

A method of testing an agent for antiangiogenic activity comprising contacting an endothelial cell with the agent and assaying for activation of Rap-1 in the endothelial cell, activation of Rap-1 in the endothelial cell being indicative of antiangiogenic activity.

### Claim 2 (depends on 1)

The method of claim 1, further comprising contacting a second endothelial cell with the agent and detecting cell flattening.

### Claim 3 (depends on 1)

The method of claim 1, wherein the endothelial cell is a human microvascular endothelial cell or a human umbilical vascular endothelial cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein activation of Rap-1 is assayed by evaluating expression of Rap-1 guanine nucleotide exchange factors (GEFs) in the cell or performing a pull-down assay for activated Rap-1.

### Claim 5 (depends on 1)

The method of claim 1, further comprising contacting a population of endothelial cells with the agent and assaying for antiangiogenic activity in the population of endothelial cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein assaying for antiangiogenic activity comprises evaluating chemotaxis in the population of endothelial cells.

### Claim 7 (depends on 5)

The method of claim 5, wherein assaying for antiangiogenic activity comprises evaluating tubule formation in the population of endothelial cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent is a cAMP analog.

### Claim 9

A method of inhibiting angiogenesis in a cell population comprising contacting one or more of the cells in the population with an agent that activates Rap-1 or the Rap-1 signaling pathway.

### Claim 10 (depends on 9)

The method of claim 9, wherein the agent is edema toxin.

### Claim 11 (depends on 9)

The method of claim 9, wherein the agent is 8CPT-2Me-cAMP, or an analog thereof.

### Claim 12 (depends on 9)

The method of claim 9, wherein the agent is a constitutively active Rap-1.

### Claim 13 (depends on 1, 9)

The method of claim 9, wherein the agent is identified by the method of claim 1.

### Claim 14 (depends on 9)

The method of claim 9, wherein the cell population comprises an in vitro cell population.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cell population comprises an in vivo cell population.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cell population comprises two or more endothelial cells within a solid tumor.

### Claim 17 (depends on 15)

The method of claim 15, wherein the agent is administered intratumorally.

### Claim 18 (depends on 16)

The method of claim 16, wherein the agent is administered to the vasculature of the solid tumor.

### Claim 19 (depends on 16)

The method of claim 16, wherein the microvessel density of the tumor is reduced.

### Claim 20 (depends on 16)

The method of claim 16, wherein the tumor volume is reduced.

### Claim 21 (depends on 15)

The method of claim 15, wherein the cell population comprises two or more endothelial cells in an ocular tissue.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cell population comprises two or more retinal or subretinal endothelial cells.

### Claim 23 (depends on 21)

The method of claim 21, wherein the agent is administered topically to the eye, intravitrally or periocularly.

### Claim 24

A method of treating a condition characterized by ocular neovascularization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that activates Rap-1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the condition is selected from the group consisting of macular degeneration, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasias, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, rubeotic glaucoma, and interstitial keratitis.

### Claim 26 (depends on 24)

The method of claim 24, wherein the agent is a cAMP analog.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cAMP analog is 8CPT-2Me-cAMP.

### Claim 28 (depends on 27)

The method of claim 27, wherein the 8CPT-2Me-cAMP is administered intravitrally, periocularly or topically to an eye of the subject.

### Claim 29 (depends on 24)

The method of claim 24, wherein the agent is a polynucleotide encoding a constitutively active Rap-1 polypeptide.

### Claim 30

An pharmaceutical composition comprising a Rap-1 activator.

### Claim 31

A method of inhibiting angiogenesis in a cell population comprising delivering to at least one cell of the cell population a polynucleotide encoding a constitutively active Rap-1 polypeptide, the polynucleotide operably connected to a promoter functional in the at least one cell to obtain expression of the Rap-1 polypeptide at a level sufficient to inhibit angiogenesis.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cell population is located in a mammalian subject.

### Claim 33 (depends on 31)

The method of claim 31, wherein the polynucleotide is comprised within a vector.

### Claim 34 (depends on 33)

The method of claim 33, wherein the vector is a liposome.

### Claim 35 (depends on 34)

The method of claim 34, wherein the vector is a viral vector.

### Claim 36 (depends on 35)

The method of claim 35, wherein the viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a vaccinia viral vector, a retroviral vector, a pox viral vector and a herpesviral vector.

### Claim 37

A kit for inhibiting angiogenesis comprising a polynucleotide encoding a constitutively active Rap-1 polypeptide.

### Claim 38

A method of inhibiting chemotaxis in a cell comprising contacting one or more cells with an agent that inhibits Rho kinase.
